Paramount stock rises after FCC approves Skydance merger
PALO ALTO, CA—Tariq Musa, a director at Guardant Health , Inc. (NASDAQ:GH), recently sold a portion of his holdings in the company. According to a filing with the Securities and Exchange Commission, Musa sold 116 shares of common stock on March 19, 2025, at a price of $43.70 per share, amid the stock’s impressive 157.89% surge over the past year. The total value of the transaction amounted to $5,069. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
Following the sale, Musa retains ownership of 3,211 shares of Guardant Health. The transaction was conducted as part of a pre-arranged trading plan. Guardant Health, a leader in the medical laboratories sector with a market capitalization of $5.55 billion and strong revenue growth of 31.04% in the last twelve months, continues to be headquartered in Palo Alto, California. For deeper insights into insider trading patterns and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Guardant Health’s Shield blood test for colorectal cancer screening has been granted Advanced Diagnostic Laboratory Test (ADLT) status by the Centers for Medicare & Medicaid Services. This designation permits a Medicare reimbursement rate of $1,495, a significant increase from the previous $920 rate, effective April 1, 2025, for a nine-month period. Analysts from TD Cowen, Citi, and Raymond (NSE:RYMD) James have all maintained positive ratings on Guardant Health, citing the potential for increased revenue and improved gross margins due to this development. TD Cowen suggests that the new ADLT rate could raise the average selling price to over $1,000 in 2025, potentially increasing revenue estimates by 2.5-3%.
Citi analysts noted that while the ADLT status was anticipated, the higher reimbursement rate was not factored into Guardant Health’s fiscal year 2025 guidance, suggesting an upside to the company’s financial forecasts. Raymond James highlighted that the new rate is expected to add roughly $14 million in revenue, impacting the company’s bottom line positively. Morgan Stanley (NYSE:MS) also raised its price target for Guardant Health shares to $52.00, reflecting confidence in the company’s growth trajectory. Guardant Health plans to use the favorable Medicare rate to expand its commercial infrastructure and make the Shield test available to a broader patient population. These developments are seen as a catalyst for enhancing Guardant Health’s financial performance in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.